



COVID-19 Vaccine and Monoclonal Antibody Infusions Policy

Effective Date: 11/09/2020

Number: RP20200001

Reimbursement Guideline

Disclaimer: EmblemHealth has policies in place that reflect billing or claims payment processes unique to our health plans. Current billing and claims payment policies apply to all our products, unless otherwise noted. EmblemHealth will inform you of new policies or changes in policies through updates to the Provider Manual, Claims Corner and/or provider newsletters. The information presented in this policy is accurate and current as of the date of this publication.

The information provided in EmblemHealth's policies is intended to serve only as a general reference resource for services described and is not intended to address every aspect of a reimbursement situation. Other factors affecting reimbursement may supplement, modify or, in some cases, supersede this policy. These factors may include, but are not limited to: legislative mandates, physician or other provider contracts, the member's benefit coverage documents and/or other reimbursement, medical or drug policies. Finally, this policy may not be implemented exactly the same way on the different electronic claims processing systems used by EmblemHealth due to programming or other constraints; however, EmblemHealth strives to minimize these variations.

EmblemHealth follows coding edits that are based on industry sources, including, but not limited to; CPT® guidelines from the American Medical Association, specialty organizations, and CMS including NCCI and MUE. In coding scenarios where there appears to be conflicts between sources, we will apply the edits we determine are appropriate. EmblemHealth uses industry-standard claims editing software products when making decisions about appropriate claim editing practices. Upon request, we will provide an explanation of how EmblemHealth's handles specific coding issues. If appropriate coding/billing guidelines or current reimbursement policies are not followed, EmblemHealth may deny the claim and/or recoup claim payment.

Overview:

The cost of COVID-19 FDA-authorized vaccine serums and monoclonal antibodies will initially be reimbursed by the government.

EmblemHealth will reimburse administration of FDA-authorized COVID-19 vaccines in accordance with applicable state federal laws, regulations and guidance, including the FFCRA, CARES Act and Emergency Use Authorization (EUA) guidance, as outlined below.

Medicare Advantage health plans: Charges for the COVID-19 vaccine administration should be billed to the CMS Medicare Administrative Contractor (Part B). The MAC will reimburse claims for Medicare members with no cost share for the remainder of 2020 and through 2021. Any claims for COVID-19 vaccines or administration charges for COVID-19 vaccines received for Medicare Advantage members will be denied and will inform the provider to resubmit to the member's MAC. For more information, see the [**CMS COVID-19 Provider Toolkit**](#).

Commercial health plans: EmblemHealth will cover the administration of COVID-19 vaccines with no cost share for in- and out-of-network providers during the national public health emergency period. Administration reimbursement will be based on CMS published rates. NY state-specific rules may also apply.

Medicaid: EmblemHealth will cover the administration of COVID-19 vaccines with no cost share for in- and out-of-network providers during the national public health emergency period. Administration reimbursement will be based on CMS published rates. NY state-specific rules and other state Medicaid regulations may apply.

Applicable Coding:

CPT Code	Description
Q0239	Injection, bamlanivimab-xxxx, 700 mg
M0239	intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring
Q0243	Injection, casirivimab and imdevimab, 2400 mg
M0243	intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose
91300	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use - Pfizer-BioNTech COVID-19 Vaccine
91301	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use -Moderna COVID-19 Vaccine

Revision History

DATE	REVISION
11/2020	<ul style="list-style-type: none"> New Policy